Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1863]

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in...

Dr Sara Hurvitz - University of California, Los Angeles, USA

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC ( Dr Sara Hurvitz - University of California, Los Angeles, USA )

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and...

Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC ( Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA )

Camizestrant may be superior to fulvestrant in patients with hormone receptor...

Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer ( Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain )

Opinion: Premature regulatory approval by the FDA

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Opinion: Premature regulatory approval by the FDA ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in...

Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC ( Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India )

HER2DX confirms the ability of the test to predict long-term survival and...

Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC ( Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain )

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Prof Jean-Yves Pierga - Institut Curie, Paris, France

Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Charles Gore - Medicines Patent Pool, Geneva, Switzerland

Access to Oncology Medicines Coalition - The Medicines Patent Pool ( Charles Gore - Medicines Patent Pool, Geneva, Switzerland )

Intraoperative ultrasound is accurate for guiding breast conservative surgery...

Dr Antonio Esgueva - Clinica Universidad de Navarra, Madrid, Spain,

Intraoperative ultrasound is accurate for guiding breast conservative surgery in non-palpable ductal breast carcinoma ( Dr Antonio Esgueva - Clinica Universidad de Navarra, Madrid, Spain, )

Addressing women’s cancers: an economic evaluation of breast and cervical...

Dr Mary Nyangasi - Head of the National Cancer Control Programme, Nairobi, Kenya

Addressing women’s cancers: an economic evaluation of breast and cervical cancer interventions in Kenya ( Dr Mary Nyangasi - Head of the National Cancer Control Programme, Nairobi, Kenya )

Long-term breast cancer risk after benign breast disease in population-based...

Dr Marta Roman - Hospital del Mar Medical Research Institute, Barcelona, Spain

Long-term breast cancer risk after benign breast disease in population-based screening ( Dr Marta Roman - Hospital del Mar Medical Research Institute, Barcelona, Spain )

EPIC study: Pre-existing cardiometabolic diseases impact cancer stage

Dr Anna Jansana - International Agency for Research on Cancer (IARC), Lyon...

EPIC study: Pre-existing cardiometabolic diseases impact cancer stage ( Dr Anna Jansana - International Agency for Research on Cancer (IARC), Lyon, France, )

More from ecancer